Ascendis Pharma AS Quote - ASND | ADVFN

S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Ascendis Pharma AS (ASND) Share Price

Ascendis Pharma AS (ASND)

135.81

1.63

(1.21%)

Closed July 07 3:00PM

Delayed by 15 minutes

135.81

0.12

(0.09%)

After Hours: 4:30PM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

135.81

Bid

120.18

Ask

180.00

Volume

107,293

132.375 Day's Range 136.30

0.00 52 Week Range 0.00

Market Cap

Previous Close

134.18

Open

134.46

Last Trade

Last Trade Time

Financial Volume

US$ 14,541,506

VWAP

135.5308

Average Volume (3m)

-

Shares Outstanding

56,614,385

Dividend Yield

-

PE Ratio

-

Earnings Per Share (EPS)

-

Revenue

-

Net Profit

-

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and ... Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.ascendispharma.com

Headquarters

Hellerup, Dnk

Founded

1970

Ascendis Pharma AS is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ASND. The last closing price for Ascendis Pharma AS was US$134.18. Over the last year, Ascendis Pharma AS shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Ascendis Pharma AS currently has 56,614,385 shares outstanding. The market capitalization of Ascendis Pharma AS is US$7.60 billion.

Pendopharm signe une entente de distribution exclusive avec Ascendis Pharma A/S pour TransCon MC PTH au Canada

Pendopharm signe une entente de distribution exclusive avec Ascendis Pharma A/S pour TransCon MC PTH au Canada Canada NewsWire MONTRÉAL, le 4 juill. 2024 MONTRÉAL, le 4 juill. 2024 /CNW/...

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL, July 4, 2024 MONTREAL, July 4, 2024 /CNW/ - Pendopharm, a...

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose •...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

COPENHAGEN, Denmark, June 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th...

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its...

Form SD - Specialized disclosure report

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SFDNXT Energy Solutions Inc	$ 0.275 (19.57%)	3.5k
GECGlobal Education Communities Corp	$ 0.355 (14.52%)	500
DSVDiscovery Silver Corp	$ 1.07 (12.63%)	617.37k
BSXBelo Sun Mining Corp	$ 0.045 (12.50%)	4k
YRBYorbeau Resources Inc	$ 0.045 (12.50%)	284k
CRWNCrown Capital Partners Inc	$ 2.21 (-26.58%)	1.37k
VGCXVictoria Gold Corp	$ 0.81 (-14.74%)	3.02M
DYADynaCERT Inc	$ 0.225 (-13.46%)	505.07k
GFRGreenfire Resources Ltd	$ 9.80 (-12.58%)	17.5k
SGNLSignal Gold Inc	$ 0.095 (-9.52%)	529.1k
TDToronto Dominion Bank	$ 75.29 (-0.76%)	15.05M
TRPTC Energy Corporation	$ 51.60 (-1.13%)	9.62M
BNSBank of Nova Scotia	$ 61.65 (-0.66%)	9.43M
SDESpartan Delta Corp	$ 4.10 (-3.53%)	6.41M
ENBEnbridge Inc	$ 48.53 (-0.86%)	6.11M

Monksdream

Monksdream 4 months ago

ASND new 52=week high

Monksdream

Monksdream 5 months ago

ASND new 52 week high

MiamiGent

MiamiGent 5 months ago

What goes down, must go up :)
Hope you banked, monk.

Monksdream

Monksdream 5 months ago

ASND new 52 week high

Monksdream

Monksdream 6 months ago

ASND new 52 week high

MiamiGent

MiamiGent 1 year ago

ASND 161 shares traded in pre-mkt. Take your profits- nobody going to hold up this dilution candidate.
Bearish

MiamiGent

MiamiGent 1 year ago

ASND After just one day of wooing, ASND is FALLING ...........in love with my short.
Irresistible attraction: fourteen-month delay on average, need for more money and a red market with housing assuring further rate increase.
Quote as of 5/02/2023 2:44PM ET
$86.375 -$0.365 (-0.421%)
Bearish
https://www.bing.com/videos/search?q=you+tube+music+roy+orbison+i%27m+falling&view=detail&mid=17436B40AE02F042D00317436B40AE02F042D003&FORM=VIRE

MiamiGent

MiamiGent 1 year ago

$ASND
A complete response letter (CRL) from the FDA delays a product’s entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them.
FDA NEWS
Bearish

MiamiGent

MiamiGent 1 year ago

ASND Net Income -$622,419,000 in 2022

Anyone want to venture a guess when the raise will come?

I'll take a WAG and say within two weeks.

MiamiGent

MiamiGent 1 year ago

ASND Quote as of 5/02/2023 10:14AM ET

$88.07 +$1.33 (+1.533%)

I'm down -3.22% on my short. Did not choose well- 100% owned by institutions.. not easily budged.
I am counting on red days, 3 day rule, CRL and outside chance of a raise- it's all I got, lol

https://stockcharts.com/h-sc/ui?s=ASND

MiamiGent

MiamiGent 1 year ago

Short today at 85.34

How long will this languish before possible good news?

Will need to raise more $$

crudeoil24

crudeoil24 3 years ago

Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric Growth Hormone Deficiency > ASND
3:46 pm ET August 25, 2021

By Stephen Nakrosis

Ascendis Pharma A/S on Wednesday said the U.S. Food and Drug Administration approved its Skytrofa as a treatment for Pediatric Growth Hormone Deficiency.

The company said Skytrofa, or lonapegsomatropin-tcgd, is the first once-weekly treatment approved to treat Pediatric Growth Hormone Deficiency.

The company also said Skytrofa was approved to treat "pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone."

The company said the approval includes its Skytrofa Auto-Injector and cartridges, which enable families to store the medicine at room temperature for up to six months.

The company said availability of Skytrofa in the U.S. is expected soon.

Ascendis said it would hold an investor conference call at 4:30 p.m. ET today.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

crudeoil24

crudeoil24 3 years ago

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Ascendis Pharma AS

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions